Skip to main content

NCT00771667 - A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With T

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


Data Specification

Available upon approval of data request


Annotated CRF

Not Available

Product Info

Generic Name
Ustekinumab
Product Name
STELARA®
Therapeutic Area
Digestive System Diseases
Enrollment
526
% Female
58.7%
% White
93.2%
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
C0743T26
Data Holder
Johnson & Johnson
Condition Studied
Crohn's Disease
Mean/Median Age (Years)
38.0

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.